We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

SDHC:NYSESmith Douglas Homes Corp. Analysis

Data as of 2026-04-30 - not real-time

$13.33

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Smith Douglas Homes is trading just above a clear support level with the 20‑day SMA marginally above the 50‑day SMA, while the MACD histogram remains negative and RSI sits below the 50 mark, indicating limited upside momentum and a bearish short‑term bias. The stock’s beta is notably above 1 and volume has been on a downtrend, reinforcing a higher‑than‑average volatility profile, and the Fear & Greed Index is in the "Extreme Greed" zone, suggesting potential over‑optimism among traders.
Fundamentally, the company’s trailing PE of roughly 14 is well beneath the industry average of over 30, and its price‑to‑book ratio hovers around 1.4, pointing to an undervalued valuation despite a 9% revenue contraction and thin profit margins. Cash balances are modest against a sizable debt load, and free cash flow remains negative, yet the firm has announced a solid Q2 closing outlook and continues to target entry‑level buyers in growth‑oriented metros. The absence of a dividend underscores the focus on reinvestment, and with a neutral technical outlook but a value‑oriented fundamental case, the stock appears positioned for a potential upside rebound if market sentiment normalizes.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Bearish MACD histogram
  • Decreasing trading volume
  • Price hovering near recent support

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • Undervalued valuation relative to industry peers
  • Projected Q2 closing volume
  • Continued exposure to entry‑level housing demand

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • Low PE and price‑to‑book suggesting upside potential
  • Strategic focus on affordable homebuyers in expanding metros
  • Potential for balance‑sheet improvement as cash flow stabilizes

Key Metrics & Analysis

Financial Health

Revenue Growth-9.40%
Profit Margin1.10%
P/E Ratio14.0
ROE16.17%
ROA8.76%
Debt/Equity10.38
P/B Ratio1.4
Op. Cash Flow$-31337000
Free Cash Flow$-4218875
Industry P/E33.3

Technical Analysis

TrendNeutral
RSI42.9
Support$12.83
Resistance$15.48
MA 20$14.07
MA 50$13.98
MA 200$17.55
MACDBearish
VolumeDecreasing
Fear & Greed Index88.07

Valuation

Target Price$13.13
Upside/Downside-1.54%
GradeUndervalued
TypeValue

Risk Assessment

Beta1.45
Volatility65.19%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.